<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781105</url>
  </required_header>
  <id_info>
    <org_study_id>CLDT600ACN03</org_study_id>
    <nct_id>NCT00781105</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B</brief_title>
  <acronym>Chinese PAC</acronym>
  <official_title>An Open-label, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The &quot;Chinese PAC&quot; study (CLDT600ACN03) will evaluate the efficacy and safety of open label
      telbivudine in 2,200 compensated Chronic Hepatitis B (CHB) adults. The primary objective of
      the study is the proportion of patients achieving undetectable HBV DNA at week 52.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2008</start_date>
  <completion_date type="Actual">September 16, 2010</completion_date>
  <primary_completion_date type="Actual">September 16, 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV DNA PCR negativity rate</measure>
    <time_frame>at 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV DNA PCR negativity rate</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA reduction</measure>
    <time_frame>from baseline to Weeks 12, 24, 36, 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg loss rate</measure>
    <time_frame>at week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBeAg seroconversion rate</measure>
    <time_frame>at week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT normalization rate</measure>
    <time_frame>at weeks 24 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AE (SAE,etc), Graded lab abnormalities</measure>
    <time_frame>at week 52</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2200</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>600 mg/day, oral tablets, once daily, 52 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 16 to 65 year of age

          -  Documented CHB defined by detectable serum HBsAg and serum HBV DNA level

          -  Willing and able to comply with the study drug regimen

          -  Written informed consent before any assessment

        Exclusion Criteria:

          -  Patient has a history of/or clinical signs/symptoms of hepatic decompensation

          -  Patient has a history of HCC or findings suggestive of possible HCC

          -  Patient has received treatment of nucleoside or nucleotide drugs whether approved or
             investigational at any time

          -  History of hypersensitivity to any of the drugs (telbivudine) or to drugs of similar
             clinical classes

          -  Patient has received IFN or other immunomodulatory treatment with 12 months before
             screening

          -  Previous treatment history with NRTIs

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia Jidong, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=5723</url>
    <description>Results for CLDT600ACN03 from the Novartis Clinical Trials Website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2008</study_first_submitted>
  <study_first_submitted_qc>October 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2008</study_first_posted>
  <last_update_submitted>February 20, 2017</last_update_submitted>
  <last_update_submitted_qc>February 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Adult</keyword>
  <keyword>HBV DNA suppression</keyword>
  <keyword>Telbivudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

